Karen Stewart, MD
Internal Medicine · Moca, PRNPI 1295755981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 26.5% of the total. 2025 is the largest year on record at $1,649, more than ten times the $18 reported in 2019. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$964
- Amgen$672
- AstraZeneca$516
- Exact Sciences$237
- GSK$226
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,607100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 87 | $1,487 |
| Novo Nordisk | 58 | $964 |
| Amgen | 21 | $672 |
| AstraZeneca | 16 | $516 |
| Exact Sciences | 13 | $237 |
| GSK | 7 | $226 |
| Bayer | 10 | $204 |
| Lilly USA, LLC | 11 | $204 |
| Esperion Therapeutics, Inc. | 5 | $188 |
| Boehringer Ingelheim | 8 | $166 |
| Insulet Corporation | 2 | $131 |
| Tolmar, Inc. | 5 | $87 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Pfizer | 3 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Abbott | 2 | $39 |
| Novartis | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Acerus Pharmaceuticals Corporation | 2 | $26 |
| Medtronic | 1 | $24 |
| Philips North America LLC | 1 | $21 |
| Antares Pharma, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Array Biopharma Inc | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,607 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $100,007 |
| JardianceEmpagliflozin | 31 | $47,727 |
| FarxigaDapagliflozin Propanediol | 48 | $47,527 |
| ProliaDenosumab | 23 | $40,652 |
| RybelsusSemaglutide | 14 | $30,238 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $28,793 |
| TrulicityDulaglutide | 18 | $24,892 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $14,377 |
| Bydureon BciseExenatide Microspheres | 14 | $13,538 |
| MounjaroTirzepatide | 13 | $13,455 |
| EliquisApixaban | 21 | $12,621 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $12,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,903 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $4,417 |
| Novolog FlexpenInsulin Aspart | 12 | $4,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $964 | $130,24688 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $166 | $59,95443 claims |
| AstraZenecaFarxiga | $516 | $47,52748 claims |
| AmgenProlia | $672 | $40,65223 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $204 | $38,34731 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $65 | $28,79334 claims |
| GSKTrelegy Ellipta, Shingrix | $226 | $14,31933 claims |
| PfizerEliquis | $53 | $12,62121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Moca
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$351K
- Ronald Collazo PaganManati$206K
- Angel VinuelaDorado$182K
- Julio JimenezSan Lorenzo$99K
- Luis Negron GarciaSan German$24K
- Jorge Torres OlmedaCoto Laurel$23K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Luis Rivera ColonRio Piedras$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.